Looking for protein stabilizing drugs with thermal shift assay

Drug Testing and Analysis

Volumn 7, Issue 9, 2015, Pages 831-834

  Andreotti, Giuseppina ^a   Monticelli, Maria ^a,b   Cubellis, Maria Vittoria ^b  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Pharmacological chaperones; Rare disease; Thermal shift assay

Indexed keywords

DIAGNOSIS; PROTEINS;

CLINICAL TRIAL; FABRY DISEASE; HIGH THROUGHPUT SCREENING; MUTANT PROTEINS; PHARMACOLOGICAL CHAPERON; RARE DISEASE; REPRODUCIBILITIES; SMALL MOLECULES; THERMAL SHIFT; THERMAL SHIFT ASSAY;

MOLECULES;

ALPHA GALACTOSIDASE; ALPHA GLUCOSIDASE; CHAPERONE; DEOXYGALACTONOJIRIMYCIN; ENZYME INHIBITOR; MIGLUSTAT; MUTANT PROTEIN; RECOMBINANT ENZYME; SOLVENT; UNCLASSIFIED DRUG; 1 DEOXYNOJIRIMYCIN; MIGALASTAT;

ASSAY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENZYME DENATURATION; ENZYME INHIBITION; ENZYME STABILITY; FABRY DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; LIGAND BINDING; MELTING POINT; NOTE; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PURIFICATION; PROTEIN UNFOLDING; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERMAL SHIFT ASSAY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GLYCOGEN STORAGE DISEASE TYPE II; HUMAN; PRECLINICAL STUDY; PROCEDURES; TEMPERATURE;

1-DEOXYNOJIRIMYCIN; ALPHA-GALACTOSIDASE; DRUG EVALUATION, PRECLINICAL; ENZYME STABILITY; FABRY DISEASE; GLYCOGEN STORAGE DISEASE TYPE II; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; TEMPERATURE;

EID: 84940956600     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1798     Document Type: Note

References (19)

1. P. Yue, Z. Li, J. Moult. Loss of protein structure stability as a major causative factor in monogenic disease. J. Mol. Biol. 2005, 353, 459.
2. G. Parenti. Treating lysosomal storage diseases with pharmacological chaperones: From concept to clinics. EMBO Mol. Med. 2009, 1, 268.
3. M. Cammisa, A. Correra, G. Andreotti, M. V. Cubellis. Fabry_CEP: A tool to identify Fabry mutations responsive to pharmacological chaperones. Orphanet J. Rare Dis. 2013, 8, 111.
4. G. Parenti, S. Fecarotta, G. la Marca, B. Rossi, S. Ascione, M. A. Donati, L. O. Morandi, S. Ravaglia, A. Pichiecchio, D. Ombrone, M. Sacchini, M. B. Pasanisi, P. De Filippi, C. Danesino, R. Della Casa, A. Romano, C. Mollica, M. Rosa, T. Agovino, E. Nusco, C. Porto, G. Andria. A chaperone enhances blood alpha-glucosidase activity in pompe disease patients treated with enzyme replacement therapy. Mol. Ther. 2014, 22, 2004.
5. K. Huynh, C. L. Partch. Analysis of protein stability and ligand interactions by thermal shift assay. Curr. Protoc. Protein Sci. 2015, 79, 28.
6. M. Vedadi, F. H. Niesen, A. Allali-Hassani, O. Y. Fedorov, P. J. Finerty Jr., G. A. Wasney, R. Yeung, C. Arrowsmith, L. J. Ball, H. Berglund, R. Hui, B. D. Marsden, P. Nordlund, M. Sundstrom, J. Weigelt, A. M. Edwards. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. P. Natl Acad. Sci. USA. 2006, 103, 15835.
7. M. C. Lo, A. Aulabaugh, G. Jin, R. Cowling, J. Bard, M. Malamas, G. Ellestad. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 2004, 332, 153.
8. U. B. Ericsson, B. M. Hallberg, G. T. Detitta, N. Dekker, P. Nordlund. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 2006, 357, 289.
9. M. W. Pantoliano, E. C. Petrella, J. D. Kwasnoski, V. S. Lobanov, J. Myslik, E. Graf, T. Carver, E. Asel, B. A. Springer, P. Lane, F. R. Salemme. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 2001, 6, 429.
10. D. Matulis, J. K. Kranz, F. R. Salemme, M. J. Todd. Thermodynamic stability of carbonic anhydrase: Measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry. 2005, 44, 5258.
11. A. Wilhelm, L. A. Lopez-Garcia, K. Busschots, W. Frohner, F. Maurer, S. Boettcher, H. Zhang, J. O. Schulze, R. M. Biondi, M. Engel. 2-(3-Oxo-1, 3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: Development and prodrug concept. J. Med. Chem. 2012, 55, 9817.
12. G. Andreotti, E. Pedone, A. Giordano, M. V. Cubellis. Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation. Mol. Genet. Genomic. Med. 2013, 1, 32.
13. G. Andreotti, I. Cabeza de Vaca, A. Poziello, M. C. Monti, V. Guallar, M. V. Cubellis. Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorder. J. Biol. Chem. 2014, 289, 34900.
14. E. R. Benjamin, R. Khanna, A. Schilling, J. J. Flanagan, L. J. Pellegrino, N. Brignol, Y. Lun, D. Guillen, B. E. Ranes, M. Frascella, R. Soska, J. Feng, L. Dungan, B. Young, D. J. Lockhart, K. J. Valenzano. Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol. Ther. 2012, 20, 717.
15. R. L. Lieberman, J. A. D'Aquino, D. Ringe, G. A. Petsko. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry. 2009, 48, 4816.
16. A. I. Guce, N. E. Clark, J. J. Rogich, S. C. Garman. The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem. Biol. 2011, 18, 1521.
17. J. J. Flanagan, B. Rossi, K. Tang, X. Wu, K. Mascioli, F. Donaudy, M. R. Tuzzi, F. Fontana, M. V. Cubellis, C. Porto, E. Benjamin, D. J. Lockhart, K. J. Valenzano, G. Andria, G. Parenti, H. V. Do. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum. Mutat. 2009, 30, 1683.
18. K. Sugawara, Y. Tajima, I. Kawashima, T. Tsukimura, S. Saito, K. Ohno, K. Iwamoto, T. Kobayashi, K. Itoh, H. Sakuraba. Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease. Mol. Genet. Metab. 2009, 96, 233.
19. G. Andreotti, V. Citro, A. Correra, M. V. Cubellis. A thermodynamic assay to test pharmacological chaperones for Fabry disease. Biochim. Biophys. Acta. 2014, 1840, 1214.